Bifogade filer
PDF
Kurs
-1,89%
Likviditet
0,47 MSEK
Kalender
| Est. tid* | ||
| 2025-11-27 | N/A | Årsstämma |
| 2025-10-30 | 07:30 | Bokslutskommuniké 2025 |
| 2025-07-24 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-04-25 | - | Kvartalsrapport 2025-Q2 |
| 2025-01-30 | - | Kvartalsrapport 2025-Q1 |
| 2024-11-29 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2024-11-28 | - | Årsstämma |
| 2024-10-24 | - | Bokslutskommuniké 2024 |
| 2024-07-25 | - | Kvartalsrapport 2024-Q3 |
| 2024-05-27 | - | Extra Bolagsstämma 2024 |
| 2024-04-25 | - | Kvartalsrapport 2024-Q2 |
| 2024-01-25 | - | Kvartalsrapport 2024-Q1 |
| 2023-12-01 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2023-11-30 | - | Årsstämma |
| 2023-10-26 | - | Bokslutskommuniké 2023 |
| 2023-07-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-04-27 | - | Kvartalsrapport 2023-Q2 |
| 2023-01-26 | - | Kvartalsrapport 2023-Q1 |
| 2022-11-25 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2022-11-24 | - | Årsstämma |
| 2022-10-27 | - | Bokslutskommuniké 2022 |
| 2022-07-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-04-28 | - | Kvartalsrapport 2022-Q2 |
| 2022-01-27 | - | Kvartalsrapport 2022-Q1 |
| 2021-11-25 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2021-11-24 | - | Årsstämma |
| 2021-10-29 | - | Bokslutskommuniké 2021 |
| 2021-07-30 | - | Kvartalsrapport 2021-Q3 |
| 2021-04-29 | - | Kvartalsrapport 2021-Q2 |
| 2021-01-29 | - | Kvartalsrapport 2021-Q1 |
| 2020-11-25 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2020-11-24 | - | Årsstämma |
| 2020-10-30 | - | Bokslutskommuniké 2020 |
| 2020-07-31 | - | Kvartalsrapport 2020-Q3 |
| 2020-06-03 | - | Extra Bolagsstämma 2020 |
| 2020-04-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-01-31 | - | Kvartalsrapport 2020-Q1 |
| 2019-12-06 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2019-12-05 | - | Årsstämma |
| 2019-10-31 | - | Bokslutskommuniké 2019 |
| 2019-07-31 | - | Kvartalsrapport 2019-Q3 |
| 2019-04-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-01-31 | - | Kvartalsrapport 2019-Q1 |
| 2018-12-05 | - | Årsstämma |
| 2018-11-01 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2018-10-31 | - | Bokslutskommuniké 2017 |
| 2018-07-31 | - | Kvartalsrapport 2017-Q3 |
| 2017-12-06 | - | X-dag ordinarie utdelning NXTCL 0.00 SEK |
| 2017-12-05 | - | Årsstämma |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NextCell Pharma AB's ("NextCell" or "the Company") has entered into a strategic collaboration with Fujifilm Irvine Scientific Inc. to bring together their core competences in mesenchymal stromal cells (MSCs) and raw materials for the life science sector. The aim of the collaboration is to provide researchers and developers in the cell therapy field with an integrated offering - standardised MSC products, optimised culture media, and cryopreservation solutions.
In 2024, NextCell expanded its portfolio by developing a research-use-only umbilical cord MSC product, manufactured using proprietary in-house expertise for the commercial market. Building on this progress, the company is now initiating a collaboration with Fujifilm Irvine Scientific Inc. ("Fujifilm") to combine this cell product with Fujifilm's established MSC media and cryopreservation product lines.
Fujifilm is a global leader in the development of high-quality cell culture solutions for the life science and medical markets. With over 50 years of industry experience, Fujifilm is recognised for its innovation and commitment to advancing areas such as cell and gene therapy.
This joint offering is expected to provide researchers and industry stakeholders with:
- Standardised, high-quality MSC reference material
- Optimised media and cryopreservation solutions for MSC culture and cold storage
- A reliable reference system for the development and validation of new therapies
"We have worked closely together to develop this business relationship and are proud to be able to announce this new opportunity to our shareholders," said Dr Lindsay Davies, CSO at NextCell.
Mathias Svahn, CEO at NextCell, added: "This is a new business venture for NextCell, and we are excited to collaborate with Fujifilm, combining our expertise to build a strong partnership for the future."
This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-05-2025 09:40 CET.
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma
For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se
Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva